B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 29, 2010, Pages 12747-12754

  Irish, Jonathan M ^a,b   Myklebust, June H ^a   Alizadeh, Ash A ^a   Houot, Roch ^a   Sharman, Jeff P ^a   Czerwinski, Debra K ^a   Nolan, Garry P ^b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

B cell receptor; Follicular lymphoma; Phospho flow cytometry; Signaling profile

Indexed keywords

CD40 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATASE; PREDNISONE; VINCRISTINE;

ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER SURVIVAL; CELL COUNT; CELL INTERACTION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOMA CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD40; B-LYMPHOCYTES; DISEASE PROGRESSION; ENZYME ACTIVATION; EXTRACELLULAR SPACE; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, FOLLICULAR; MODELS, IMMUNOLOGICAL; PHENOTYPE; PHOSPHOPROTEIN PHOSPHATASES; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 77955643156     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002057107     Document Type: Article

References (51)

1. Irish JM, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118:217-228. (Pubitemid 38962577)
2. Kotecha N, et al. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14: 335-343.
3. Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: Mirage or reality? Nat Med 15:1010-1012.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
5. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475.
6. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
7. Martin GS (2003) Cell signaling and cancer. Cancer Cell 4:167-174.
8. Dave SS, et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169.
9. Glas AM, et al. (2007) Gene-expression and immunohistochemical study of specific Tcell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390-398.
10. Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2:945-956. (Pubitemid 37323215)
11. Reth M, Brummer T (2004) Feedback regulation of lymphocyte signalling. Nat Rev Immunol 4:269-277.
12. Kurosaki T, Shinohara H, Baba Y (2010) B cell signaling and fate decision. Annu Rev Immunol 28:21-55.
13. Chen L, et al. (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111:2230-2237. (Pubitemid 351451430)
14. Stevenson FK, Caligaris-Cappio F (2004) Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103:4389-4395. (Pubitemid 38745961)
15. Küppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5: 251-262.
16. Gururajan M, Jennings CD, Bondada S (2006) Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 176:5715-5719.
17. Zhu D, et al. (2002) Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99:2562-2568. (Pubitemid 34525446)
18. Lam KP, Kühn R, Rajewsky K (1997) In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90:1073-1083.
19. Srinivasan L, et al. (2009) PI3 kinase signals BCR-dependent mature B cell survival. Cell 139:573-586.
20. Ruiz-Vela A, et al. (2008) Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. Blood 111:1665-1676. (Pubitemid 351213458)
21. Brás A, Ruiz-Vela A, González de Buitrago G, Martinez-A C (1999) Caspase activation by BCR cross-linking in immature B cells: Differential effects on growth arrest and apoptosis. FASEB J 13:931-944. (Pubitemid 29220705)
22. Irish JM, Czerwinski DK, Nolan GP, Levy R (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108:3135-3142.
23. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML (1988) Expression in non- Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318:1638-1644.
24. Silva CM (2004) Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23:8017-8023.
25. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22. (Pubitemid 37328883)
26. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501. (Pubitemid 37328931)
27. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759. (Pubitemid 41400849)
28. Calò V, et al. (2003) STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 197:157-168. (Pubitemid 37485244)
29. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308: 523-529. (Pubitemid 40570578)
30. Janes KA, et al. (2006) The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell 124:1225-1239.
31. Bagley CM, Jr, Devita VT, Jr, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227-234.
32. Solal-Céligny P, et al. (2004) Follicular lymphoma international prognostic index. Blood 104:1258-1265. (Pubitemid 39166497)
33. Hikida M, et al. (2009) PLC-gamma2 is essential for formation and maintenance of memory B cells. J Exp Med 206:681-689.
34. Chen L, et al. (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111:2230-2237. (Pubitemid 351451430)
35. Harris NL, et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392. (Pubitemid 24273002)
36. Meeker T, et al. (1985) Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658-1665. (Pubitemid 15068572)
37. Irish JM, Czerwinski DK, Nolan GP, Levy R (2006) Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 177: 1581-1589.
38. Reth M (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 3:1129-1134. (Pubitemid 35469696)
39. Singh DK, et al. (2005) The strength of receptor signaling is centrally controlled through a cooperative loop between Ca2+ and an oxidant signal. Cell 121:281-293.
40. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA (2006) Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 108:3428-3433.
41. Braselmann S, et al. (2006) R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319:998-1008.
42. Kawabe T, et al. (1994) The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167-178. (Pubitemid 2102409)
43. Mizuno T, Rothstein TL (2005) B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma. J Immunol 174:6062-6070. (Pubitemid 40663794)
44. Wheeler K, Pound JD, Gordon J, Jefferis R (1993) Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur J Immunol 23: 1165-1168. (Pubitemid 23120182)
45. Maloney DG, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
46. Marcus R, et al. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586.
47. Hochster H, et al. (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study. J Clin Oncol 27:1607-1614.
48. Johnson NA, et al. (2009) Diffuse large B-cell lymphoma: Reduced CD20 expression is associated with an inferior survival. Blood 113:3773-3780.
49. Bahler DW, Levy R (1992) Clonal evolution of a follicular lymphoma: Evidence for antigen selection. Proc Natl Acad Sci USA 89:6770-6774.
50. Zelenetz AD, Chen TT, Levy R (1992) Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 176:1137-1148.
51. Radcliffe CM, et al. (2007) Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 282:7405-7415.